Genetically engineered smooth muscle cells as linings to improve the biocompatibility of cardiovascular prostheses

Circulation

Volumn 94, Issue 9 SUPPL., 1996, Pages

  Scott Burden, Timothy ^a,b   Tock, Christine L ^a   Schwarz, John J ^a   Casscells, S Ward ^a   Engler, David A ^a  

^a EAST TEXAS MEDICAL CENTER   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

genes; heart assist device; muscle, smooth

Indexed keywords

ANIMAL TISSUE; ARTICLE; ASSISTED CIRCULATION; BIOCOMPATIBILITY; CELL PROLIFERATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENETIC ENGINEERING; HEART VALVE PROSTHESIS; IMPLANTATION; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER;

ANIMALS; BIOCOMPATIBLE MATERIALS; CATTLE; CELLS, CULTURED; EPOPROSTENOL; GENETIC ENGINEERING; GTP CYCLOHYDROLASE; HEART-ASSIST DEVICES; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 0011186825     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Frazier OH, Rose EA, Macmanus Q, Burton NA, Lefrak EA, Poirier VL, Dasse KA. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device. Ann Thorac Surg. 1992;53:1080-1090.
2. Frazier OH, Rose EA, McCarthy P, Burton NA, Tector A, Levin H, Kayne HL, Poirier VL, Dasse KA. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg. 1995;222:327-338.
3. Frazier OH, Baldwin RT, Eskin SG, Duncan JM. Immunochemical identification of human endothelial cells on the lining of a ventricular assist device. Tex Heart Inst J. 1993;20:78-82.
4. Scott-Burden T, Frazier OH. Cellular linings of ventricular assist devices. Ann Thorac Surg. In press.
5. Scott-Burden T, Schini VB, Elizondo E, Junquero DC, Vanhoutte PM. Platelet derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells: effects on proliferation. Circ Res. 1992; 71:1088-1100.
6. Von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.
7. Scott-Burden T. Regulation of nitric oxide production by tetrahydrobiopterin. Circulation. 1995;91:248-250.
8. Scott-Burden T, Resink TJ, Baur U, Burgin M, Buhler FR. Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats. Hypertension. 1989;13:295-304.
9. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cell. Nature. 1985; 313:812-815.
10. Scott-Burden T, Elizondo E, Ge T, Boulanger CM, Vanhoutte PM. Simultaneous activation of adenylyl cyclase and protein kinase C induces production of nitric oxide by vascular smooth muscle cells. Mol Pharmacol. 1994;46:274-282.
11. Yao S-K, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, Buja LM, Willerson JT. Endogenous nitric oxide protects against aggregation and cyclic flow variations in stenosed and endothelium-injured vessels. Circulation. 1992;86:1302-1309.
12. Xu X-M, Ohashi K, Ruan K-H, Wang L-H, Wu KK. Enhanced prostacyclin synthesis in endothelial cells by retrovirus-mediated transfer of prostacyclin H synthase cDNA. J Clin Invest. 1993; 91:1843-1849.
13. 2 and nitric oxide donor molsidomine have synergistic effects on thromboresistance in man. Br J Clin Pharmacol. 1992;33:289-292.